SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-016394
Filing Date
2022-06-10
Accepted
2022-06-10 10:59:54
Documents
12
Period of Report
2022-06-09
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 34291
  Complete submission text file 0001493152-22-016394.txt   207037

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gtbp-20220609.xsd EX-101.SCH 2968
3 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gtbp-20220609_lab.xml EX-101.LAB 34240
4 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gtbp-20220609_pre.xml EX-101.PRE 22365
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3636
Mailing Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005
Business Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 221007980
SIC: 2834 Pharmaceutical Preparations